Barinthus’ HPV therapy meets primary endpoint in Phase I/II trial
The UK-based Barinthus Biotherapeutics (formerly Vaccitech) has released topline data from its Phase Ib/II APOLLO trial for its human papillomavirus (HPV) treatment, VTP-200. The randomised placebo-controlled APOLLO trial (NCT04607850) met its primary …